Methods for inhibiting angiogenesis and or lymphangiogenesis
Proprotein convertase inhibitor has been found to block proteolytic processing and activation of VEGF-C and VEGF-D and inhibit angiogenesis and/or lymphangiogenesis. Method and composition are disclosed for inhibiting angiogenesis and/or lymphangiogenesis, and for treating conditions associated with excessive angiogenesis, such as tumors and/or retinopathies, as well as conditions associated with lymphangiogenesis, such as the metastatic spread of malignancies, macular degeneration, inflammatory mediated diseases, rheumatoid arthritis, diabetic retinopathy and psoriasis in a patient. The inventive method and composition utilize proprotein convertase antagonist selected from the group consisting of an anti-proprotein convertase antibody, an antisense nucleic acid molecule against a polynucleotide coding for a proprotein convertase, and an siRNA for inhibiting proprotein convertase expression, as well as proprotein convertase inhibitors.
1 . A method of inhibiting angiogenesis or lymphangiogenesis comprising administering to an organism in need thereof an effective angiogenesis or lymphangiogenesis inhibiting amount of a proprotein convertase inhibitor.
2 . A method according to claim 1 , wherein said proprotein convertase inhibitor is selected from the group consisting of inhibitory prosegments of proprotein convertases, inhibitory variants of antitrypsin and peptidyl haloalkyl ketone inhibitors.
3 . A method according to claim 2 , wherein said proprotein convertase inhibitor comprises an inhibitory prosegement of a proprotein convertase selected from the group consisting of PACE4, PC1, PC2, PC3, PC4, PC5A, PC5B, PC6A, PC6B, PC7 and Furin
4 . A method according to claim 3 , wherein said proprotein convertase inhibitor comprises an inhibitory prosegment of Furin or PC7.
5 . A method according to claim 2 , wherein said proprotein convertase inhibitor is a peptidyl haloalkyl ketone inhibitor selected from the group consisting of decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-CMK), decanoyl-Phe-Ala-Lys-Arg-chloromethylketone (Dec-FAKR-CMK), decanoyl-Arg-Glu-Ile-Arg-chloromethylketone (Dec-REIR-CMK), and decanoyl-Arg-Glu-Lys-Arg-chloromethylketone (Dec-REKR-CMK).
6 . A method according to claim 5 , wherein said proprotein convertase inhibitor comprises decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-CMK).
7 . A method according to claim 2 , wherein said proprotein convertase inhibitor is an inhibitory variant of antitrypsin.
8 . A method according to claim 7 , wherein said proprotein convertase inhibitor comprises α-1 antitrypsin Portland.
9 . A method according to claim 1 , wherein said organism is suffering from a tumor.
10 . A method according to claim 1 , wherein said organism is suffering from macular degeneration.
11 . A method according to claim 1 , wherein said organism is a mammal.
12 . A method according to claim 11 , wherein said mammal is human.
13 . A method of inhibiting angiogenesis or lymphangiogenesis comprising administering to an organism in need thereof an effective angiogenesis or lymphangiogenesis inhibiting amount of a proprotein convertase antagonist selected from the group consisting of an anti-proprotein convertase antibody, an antisense nucleic acid molecule against a polynucleotide coding for a proprotein convertase, and an siRNA for inhibiting proprotein convertase expression.
14 . A pharmaceutical composition for inhibiting angiogenesis or lymphangiogenesis in a patient in need thereof, the composition comprising an effective angiogenesis or lymphangiogenesis inhibiting amount of a proprotein convertase inhibitor, or an antagonist selected from the group consisting of an anti-proprotein convertase antibody, an antisense nucleic acid molecule against a polynucleotide coding for a proprotein convertase, and an siRNA for inhibiting proprotein convertase expression, and a pharmaceutically acceptable excipient.
15 . A method of treating a condition selected from the group consisting of cancer, tumor growth, tumor metastasis, macular degeneration, inflammatory mediated diseases, rheumatoid arthritis, diabetic retinopathy and psoriasis in a patient, said method comprising administering to said patient an effective amount of a pharmaceutical composition of claim 14 .
16 . A method according to claim 15 , wherein the method is for inhibiting tumor growth and the pharmaceutical composition comprises an effective tumor growth inhibiting amount of a proprotein convertase inhibitor.
17 . A method according to claim 15 , wherein the method is for inhibiting cancer metastasis and the pharmaceutical composition comprises an effective tumor growth inhibiting amount of a proprotein convertase inhibitor.
18 . A method according to claim 15 , wherein the method is for treating an inflammatory disease and the pharmaceutical composition comprises an effective tumor growth inhibiting amount of a proprotein convertase inhibitor.
19 . A method according to claim 18 , wherein said inflammatory disease is rheumatoid arthritis.
20 . A method according to claim 15 , wherein said proprotein convertase inhibitor is selected from the group consisting of inhibitory prosegments of proprotein convertases, inhibitory variants of antitrypsin and peptidyl haloalkyl ketone inhibitors.
21 . A pharmaceutical composition according to claim 14 , wherein said proprotein convertase inhibitor is selected from the group consisting of inhibitory prosegments of proprotein convertases, inhibitory variants of antitrypsin and peptidyl haloalkyl ketone inhibitors.
22 . A pharmaceutical composition according to claim 21 , wherein said inhibitory prosegement of a proprotein convertase selected from the group consisting of PACE4, PC1, PC2, PC3, PC4, PC5A, PC5B, PC6A, PC6B, PC7 and Furin
23 . A method according to claim 22 , wherein said proprotein convertase inhibitor comprises an inhibitory prosegment of Furin or PC7.